Ocugen Inc - Company Profile
Powered by 
All the data and insights you need on Ocugen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Ocugen Inc Strategy Report
- Understand Ocugen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ocugen Inc (Ocugen) Is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment. It is investigating OCU-400 against NR2E3, RHO, CEP290, and PDE6B mutation-associated retinal degeneration; and OCU-410 targeting dry age-related macular degeneration. The company is developing OCU200 drugs to treat diabetic macular edema, diabetic retinopathy, and wet-age-related macular degeneration. Ocugen is also investing OCU410ST for stargardt orphan disease. It utilizes a modified gene therapy platform to develop its products. The company operates in Ireland and the US. Ocugen is headquartered in Malvern, Pennsylvania, the US.
Headquarters
United States of America
Address
11 Great Valley Parkway, Malvern, Pennsylvania, 19355
Website
ocugen.com
Telephone
1 484 3284701
No of Employees
65
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OCGN (NASD)
Revenue (2022)
$6.0M
142.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
27.3%
(2022 vs 2021)
Market Cap*
$329.4M
Net Profit Margin (2022)
XYZ
70.1%
(2022 vs 2021)
* As of and is in US$
Ocugen Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| COVAXIN™ (BBV152): |
| Covid-19 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In April, the company received approval from the U.S. Food and Drug Administration for the company’s Investigational New Drug amendment to initiate a Phase 3 clinical trial of OCU400. |
| 2024 | Plans/Strategy | In April, the company announced its plans to initiate a Phase III trial of its gene therapy candidate OCU400 for retinitis pigmentosa. |
| 2023 | Regulatory Approval | In March, the company announced that the Food and Drug Administration approved enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial. |
Competitor Comparison
| Key Parameters | Ocugen Inc | Editas Medicine Inc | MeiraGTx Holdings Plc | Adverum Biotechnologies Inc | Beacon Therapeutics (USA) Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Malvern | Cambridge | New York | Redwood City | Alachua |
| State/Province | Pennsylvania | Massachusetts | New York | California | Florida |
| No. of Employees | 65 | 265 | 419 | 121 | 102 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shankar Musunuri, Ph.D. | Chief Executive Officer; Chairman | Executive Board | 2019 | 59 |
| Quan An Vu | Chief Business Officer; Chief Financial Officer | Senior Management | 2023 | 51 |
| Huma Qamar | Chief Medical Officer | Senior Management | 2024 | - |
| Arun Upadhyay | Head - Research, Development and Medical; Chief Scientific Officer | Senior Management | 2022 | 41 |
| Ranjit R. Deshmukh | Vice President - Manufacturing and Supply | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer